Understanding the Lethal Variant of Prostate Cancer: Power of Examining Extremes

DOI PDF 2 Citations
  • Ana Aparicio
    Authors' Affiliation: Department of Genitourinary Medical Oncology, David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • Christopher J. Logothetis
    Authors' Affiliation: Department of Genitourinary Medical Oncology, David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • Sankar N. Maity
    Authors' Affiliation: Department of Genitourinary Medical Oncology, David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas

Description

<jats:title>Abstract</jats:title><jats:p>Small cell prostate carcinoma is a lethal variant of castration-resistant prostate cancer. Beltran and colleagues identified overexpression and amplification of both aurora kinase A (AURKA) and the MYCN proto-oncogene in the small cell prostate carcinomas and propose Aurora kinase A as a potential therapeutic target in this disease subset. Cancer Discovery; 1(6); 466–68. ©2011 AACR.</jats:p><jats:p>Commentary on Beltran et al., p. 487.</jats:p>

Journal

  • Cancer Discovery

    Cancer Discovery 1 (6), 466-468, 2011-11-01

    American Association for Cancer Research (AACR)

Citations (2)*help

See more

Details 詳細情報について

Report a problem

Back to top